Metabolic risk during antipsychotic treatmentNEWCOMER, John W.Clinical therapeutics. 2004, Vol 26, Num 12, pp 1936-1946, issn 0149-2918, 11 p.Article

Medical risk in patients with bipolar disorder and schizophreniaNEWCOMER, John W.The Journal of clinical psychiatry. Supplement. 2006, Vol 67, Num 9, pp 25-30, 6 p.Conference Paper

Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature reviewNEWCOMER, John W.CNS drugs. 2005, Vol 19, Num 1, pp 1-93, issn 1172-7047, 93 p., SUP1Article

Abnormalities of glucose metabolism associated with atypical antipsychotic drugsNEWCOMER, John W.The Journal of clinical psychiatry. Supplement. 2004, Vol 65, Num 18, pp 36-46, 11 p.Article

Metabolic considerations in the use of antipsychotic medications : A review of recent evidenceNEWCOMER, John W.The Journal of clinical psychiatry. Supplement. 2007, Vol 68, Num 1, pp 20-27, 8 p.Conference Paper

Antipsychotic medications: Metabolic and cardiovascular riskNEWCOMER, John W.The Journal of clinical psychiatry. Supplement. 2007, Vol 68, Num 4, pp 8-13, 6 p.Article

Are the cardiometabolic complications of schizophrenia still neglected? Barriers to careLAMBERT, Tim J. R; NEWCOMER, John W.Medical journal of Australia. 2009, Vol 190, Num 4, issn 0025-729X, S39-S42, SUPArticle

Atypical antipsychotics and Metabolic dysregulation: Evaluating the risk/benefit equation and improving the standard of careNASRALLAH, Henry A; NEWCOMER, John W.Journal of clinical psychopharmacology. 2004, Vol 24, Num 5, pp S7-S14, issn 0271-0749, SUP1Article

Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients With Comorbid Medical IllnessesNEWCOMER, John W.The Journal of clinical psychiatry. Supplement. 2009, Vol 70, Num 3, pp 30-36, 7 p.Article

The metabolic effects of antipsychotic medications : Metabolic effects of antipsychotic treatment: between a rock and a hard place?NEWCOMER, John W; HAUPT, Dan W.Canadian journal of psychiatry. 2006, Vol 51, Num 8, pp 480-491, issn 0706-7437, 12 p.Article

Hyperglycemia and antipsychotic medicationsHAUPT, Dan W; NEWCOMER, John W.The Journal of clinical psychiatry. Supplement. 2001, Vol 62, Num 27, pp 15-26Conference Paper

Switching Antipsychotic Medications to Reduce Adverse Event Burden in Schizophrenia: Establishing Evidence-Based PracticeNEWCOMER, John W; WEIDEN, Peter J; BUCHANAN, Robert W et al.The Journal of clinical psychiatry. 2013, Vol 74, Num 11, pp 1108-1120, issn 0160-6689, 13 p.Article

The atypical antipsychotic therapy and metabolic issues national survey: Practice patterns and knowledge of psychiatristsNEWCOMER, John W; NASRALLAH, Henry A; LOEBEL, Antony D et al.Journal of clinical psychopharmacology. 2004, Vol 24, Num 5, pp S1-S6, issn 0271-0749, SUP1Article

Treatment-related alteration of cortisol predicts change in neuropsychological function during acute treatment of late-life anxiety disorderLENZE, Eric J; DIXON, David; MANTELLA, Rose C et al.International journal of geriatric psychiatry. 2012, Vol 27, Num 5, pp 454-462, issn 0885-6230, 9 p.Article

Comorbid Somatic Illnesses in Patients With Severe Mental Disorders : Clinical, Policy, and Research ChallengesFLEISCHHACKER, W. Wolfgang; CETKOVICH-BAKMAS, Marcelo; OLFSON, Mark et al.The Journal of clinical psychiatry. 2008, Vol 69, Num 4, pp 514-519, issn 0160-6689, 6 p.Article

Abnormalities in glucose regulation during antipsychotic treatment of schizophreniaNEWCOMER, John W; HAUPT, Dan W; FUCETOLA, Robert et al.Archives of general psychiatry. 2002, Vol 59, Num 4, pp 337-345, issn 0003-990XArticle

Antidepressant Drug Compliance: Reduced Risk of MI and Mortality in Depressed PatientsSCHERRER, Jeffrey F; GARFIELD, Lauren D; NEWCOMER, John W et al.The American journal of medicine. 2011, Vol 124, Num 4, pp 318-324, issn 0002-9343, 7 p.Article

Long-Term Changes in Weight and Plasma Lipids during Maintenance Treatment with ZiprasidoneWEIDEN, Peter J; NEWCOMER, John W; LOEBEL, Antony D et al.Neuropsychopharmacology (New York, NY). 2008, Vol 33, Num 5, pp 985-994, issn 0893-133X, 10 p.Article

Metabolic Risk Status and Second-Generation Antipsychotic Drug Selection : A Retrospective Study of Commercially Insured PatientsMORRATO, Elaine H; CUFFEL, Brian; NEWCOMER, John W et al.Journal of clinical psychopharmacology. 2009, Vol 29, Num 1, pp 26-32, issn 0271-0749, 7 p.Article

Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and DiabetesMORRATO, Elaine H; NEWCOMER, John W; KAMAT, Siddhesh et al.Diabetes care. 2009, Vol 32, Num 6, pp 1037-1042, issn 0149-5992, 6 p.Article

Prevalence of Baseline Serum Glucose and Lipid Testing in Users of Second-Generation Antipsychotic Drugs : A Retrospective, Population-Based Study of Medicaid Claims DataMORRATO, Elaine H; NEWCOMER, John W; ALLEN, Richard R et al.The Journal of clinical psychiatry. 2008, Vol 69, Num 2, pp 316-322, issn 0160-6689, 7 p.Article

Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristoneLENZE, Eric J; HERSHEY, Tamara; NEWCOMER, John W et al.International journal of geriatric psychiatry. 2014, Vol 29, Num 9, pp 962-969, issn 0885-6230, 8 p.Article

Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot studytLENZE, Ericj; SKIDMORE, Elizabeth R; BEGLEY, AmyE et al.International journal of geriatric psychiatry. 2012, Vol 27, Num 9, pp 974-980, issn 0885-6230, 7 p.Article

Neural Correlates of Weight Gain With OlanzapineMATHEWS, Jose; NEWCOMER, John W; MATHEWS, Jennifer R et al.Archives of general psychiatry. 2012, Vol 69, Num 12, pp 1226-1237, issn 0003-990X, 12 p.Article

Prevalence and Predictors of Lipid and Glucose Monitoring in Commercially Insured Patients Treated With Second-Generation Antipsychotic AgentsHAUPT, Dan W; ROSENBLATT, Lisa C; KIM, Edward et al.The American journal of psychiatry. 2009, Vol 166, Num 3, pp 345-353, issn 0002-953X, 9 p.Article